Last Updated : April 29, 2025
The provisional algorithm process is used to give advice to drug programs when they have indicated a need to harmonize the place in therapy for the funding of the drug under review relative to alternative treatments that are currently reimbursed by the public drug programs. The process helps to determine the impact of new therapies on the existing reimbursement sequence. While broad in scope, funding algorithms are focused on reimbursement decision-making; they are not treatment algorithms or guidelines and do not fully detail the clinical management of cancer patients.
We will initiate the development of a provisional algorithm in the following instances:
Please review the Procedures for Reimbursement Reviews for complete details.
We issue a call for stakeholder input at the time the provisional algorithm project is initiated and seeks stakeholder feedback on the draft provisional algorithm. The following stakeholders are eligible to contribute: patient groups, clinician groups, the participating drug programs, and drug manufacturers whose products may be directly impacted by the provisional algorithm.
Open calls for input and feedback are highlighted in the Weekly Update and instructions for contributing are provided below.
To provide initial input at the outset of the provisional algorithm project:
To provide stakeholder feedback on a draft provisional algorithm report:
Updates on provisional funding algorithms are posted to this page. Reports are searchable and freely available to anyone to use, download, or print for non-commercial and personal use, or private research and study, provided you do not modify them, and appropriate credit is given to us.